KLP Kapitalforvaltning AS Buys 26,300 Shares of Boston Scientific Corporation $BSX

KLP Kapitalforvaltning AS grew its stake in Boston Scientific Corporation (NYSE:BSX) by 4.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 614,056 shares of the medical equipment provider’s stock after acquiring an additional 26,300 shares during the period. KLP Kapitalforvaltning AS’s holdings in Boston Scientific were worth $65,956,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of BSX. HM Payson & Co. lifted its holdings in shares of Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. IVC Wealth Advisors LLC raised its holdings in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after buying an additional 102 shares during the period. Park Square Financial Group LLC raised its holdings in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC lifted its stake in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 103 shares in the last quarter. Finally, Rise Advisors LLC boosted its holdings in shares of Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 103 shares during the period. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $17,972,457 in the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX opened at $96.73 on Tuesday. The business’s 50-day simple moving average is $102.75 and its 200 day simple moving average is $102.04. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market capitalization of $143.33 billion, a PE ratio of 57.58, a PEG ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue was up 22.8% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Barclays raised their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Truist Financial upped their price objective on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Canaccord Genuity Group increased their price objective on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Finally, Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and a consensus price target of $120.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.